Drug Profile
Research programme: protein tyrosine phosphatase inhibitors - Novelion Therapeutics
Alternative Names: PTP inhibitors - KinetekLatest Information Update: 30 Nov 2016
Price :
$50
*
At a glance
- Originator Kinetek Pharmaceuticals
- Class
- Mechanism of Action Protein-tyrosine-phosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Nov 2016 QLT acquired Aegerion Pharmaceuticals and later QLT changed its name to Novelion Therapeutics
- 20 Feb 2008 Discontinued - Preclinical for Cancer in Canada (unspecified route)
- 04 Apr 2003 No development reported - Preclinical for Cancer in Canada (unspecified route)